488149-34-4

Usage

Uses

Used in Pharmaceutical Industry:
2-chloro-N-methoxy-N-methylnicotinamide is utilized as a pharmaceutical intermediate for the synthesis of various drugs and active pharmaceutical ingredients (APIs). Its unique chemical structure and properties make it a crucial building block in the development of new pharmaceuticals for a range of medical applications.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2-chloro-N-methoxy-N-methylnicotinamide is employed as a starting material or a key component in the design and synthesis of novel compounds with potential therapeutic effects. Its presence in these compounds can influence their pharmacological profiles, including their anti-inflammatory and analgesic properties.
Used in Drug Development:
2-chloro-N-methoxy-N-methylnicotinamide is used in drug development as a precursor in the creation of new therapeutic agents. Its chemical versatility allows for the modification of its structure to enhance the efficacy, selectivity, and safety of the resulting pharmaceuticals.
Used in Chemical Synthesis:
Beyond its pharmaceutical applications, 2-chloro-N-methoxy-N-methylnicotinamide is also used in chemical synthesis for the preparation of other organic compounds, leveraging its reactivity and functional groups to form a variety of chemical products.

Upstream product

• 49609-84-9 2-Chloronicotinoyl chloride 
• 16645-06-0 N,N-dimethylhydroxylamine hydrochloride 
• 2942-59-8 2-chloronicotinic acid 
• 30289-28-2 N-methoxy-N-methylcarbamoyl chloride 
• 1117-97-1 N,0-dimethylhydroxylamine 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 

Downstream Products

• 80099-85-0 2-chloro-3-(4-chlorobenzoyl)-pyridine 
• 1146523-97-8 1-(2-chloropyridin-3-yl)-3-(3-fluorophenyl)prop-2-yn-1-one 
• 791119-13-6 3-(4-chlorophenyl-2-chloropyrid-3-ylmethoxy)azetidine 
• 1186316-75-5 VER-156085 
• 1186316-73-3 VER-156084 
• 1186316-76-6 VER-24052 
• 1357306-02-5 C₁₆H₁₃Cl₃N₂O₂ 
• 791119-12-5 1-benzhydyryl-3-(4-chlorophenyl-2-chloropyrid-3-ylmethoxy)azetidine 
• 1357305-47-5 {3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl}pyrrolidin-1-ylmethanone 
• 1357305-50-0 {3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl}morpholin-4-ylmethanone 
• 1357305-51-1 {3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl}(2-methylpiperidin-1-yl)methanone 
• 1357305-52-2 {3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl}(3-methylpiperidin-1-yl)methanone 
• 1357305-53-3 {3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl}(4-methylpiperidin-1-yl)methanone 
• 1357305-54-4 {3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl}(4-methylpiperazin-1-yl)methanone 

Relevant academic research and scientific papers

A Novel Synthesis of 1-Alkyl-2-phenyl-1,8-naphthyridin-4-one

Provided is a novel method for manufacturing 1-alkyl-2-phenyl-1,8-naphthyridin-4-one from 2-chloronicotinic acid. According to the present invention, 1-alkyl-2-phenyl-1,8-naphthyridin-4-one can be synthesized through simple reaction conditions and simple

THIAZOLE DERIVATIVES FOR THE TREATMENT OF ANIMAL TRYPANOSOMIASIS

The present invention relates to a novel class of compounds of general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, X and Y are as defined herein, to their use in human and veterinary medicine, and in the treatment of animal trypanosomiasis in particular, to compositions containing them, to processes for their preparation and to intermediates used in such processes.

CONDENSED HETEROCYCLIC COMPOUND

The present invention provides a compound having a superior PDE10A inhibitory action and use thereof. The compound is a compound represented by the following formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.

Synthesis and biological evaluation of imidazo[4,5-b]pyridine and 4-heteroaryl-pyrimidine derivatives as anti-cancer agents

A series of N-phenyl-imidazo[4,5-b]pyridin-2-amines, 4-indazolyl-N- phenylpyrimidin-2-amines and N-phenyl-4-pyrazolo[3,4-b]pyridin-pyrimidin-2- amines have been synthesized. Their anti-proliferative activities were tested in HCT-116 human colon carcinoma and MCF-7 breast carcinoma cell lines. Many exhibited potent anti-proliferative and CDK9 inhibitory activities. A lead compound 18b demonstrated the ability to reduce the level of Mcl-1 anti-apoptotic protein, to activate caspase 3/7 and induce cancer cell apoptosis.

FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL AGENT COMPRISING SAME

The present invention provides a low molecular weight compound having EPO production-promoting action and/or hemoglobin production-promoting action. The present invention relates to a fused piperidine compound represented by the following general formula

Fatty acid amide hydrolase inhibitors. 3: Tetra-substituted azetidine ureas with in vivo activity

We describe here our attempts to optimise the human fatty acid amide hydrolase (FAAH) inhibition and physicochemical properties of our previously reported tetrasubstituted azetidine urea FAAH inhibitor, VER-156084. We describe the SAR of a series of analogues and conclude with the demonstration of in vivo dose-dependant FAAH inhibition in an anandamide-loading study in rats.

Identification of an adamantyl azaquinolone JNK selective inhibitor

3-[4-((1S,2S,3R,5S,7S)-5-Hydroxyadamantan-2-ylcarbamoyl)benzyl] -4-oxo-1-phenyl-1,4-dihydro-[1,8]naphthyridine-2-carboxylic acid methyl ester (4) was identified as a novel, druglike and selective quinolone pan JNK inhibitor. In this communication, some of the structure-activity relationship of the azaquinolone analogues leading to 4 is discussed. The focus is on how changes at the amide functionality affected the biochemical potency, cellular potency, metabolic properties, and solubility of this class of JNK inhibitors. Optimization of these properties led to the identification of the adamantyl analogue, 4. 4 achieved proof of mechanism in both rat and mouse TNF-α challenge models.

ADAMANTYL COMPOUNDS

The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are

FUSED DERIVATIVES AS PI3Kdelta INHIBITORS

The present invention provides fused derivatives that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.